Want to see AU:HCT full AI Analyst Report?
HCT Stock Chart & Stats
AU$0.09
<AU$0.01(10.00%)
At close: 4:00 PM EST
AU$0.09
<AU$0.01(10.00%)
Day’s Range― - ―
52-Week RangeAU$0.05 - AU$0.11
Previous CloseN/A
Volume829.52K
Average Volume (3M)72.05K
Market Cap
AU$29.43M
Enterprise ValueAU$20.11M
Total Cash (Recent Filing)AU$2.16M
Total Debt (Recent Filing)AU$1.59M
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding367,834,350
10 Day Avg. Volume123,924
30 Day Avg. Volume72,050
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)28.04
Price to Sales (P/S)5.45
P/FCF Ratio-20.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Revenue ModelMultiple monetization channels — direct-to-consumer product sales, B2B ingredient supply, contract manufacturing and licensing — reduce single-channel concentration risk. This structural diversity supports more stable long-term revenue opportunities and multiple paths to scale as each channel can be expanded independently.
Proprietary Formulations And IP PotentialOwning proprietary ingredients and formulations creates durable differentiation and potential licensing revenue, supporting higher margins and partner-led distribution. IP-led products can lock in B2B customers and enable recurring revenues from formulations, underpinning long-term competitive positioning.
Gross Margin RecoveryAn uptick in gross margin indicates improving unit economics and better cost or mix management versus the prior year. Sustained margin recovery would be a structural positive, enabling the company to better absorb fixed costs and reduce the reliance on external funding if the trend continues.
Bears Say
Sharp Revenue ContractionA severe decline in reported revenue signals fundamental demand weakness or lost customer contracts and undermines scale economics. Persistently lower top-line reduces ability to cover fixed costs, compromises margin recoveries, and makes profitable growth and investment more difficult without a clear revenue turnaround.
Persistent Negative Operating And Free Cash FlowContinual OCF and FCF deficits indicate the business burns cash to run operations and cannot self-fund growth or capex. Over months this forces reliance on external financing or equity dilution, constrains R&D/manufacturing investment, and heightens execution risk until cash generation turns positive.
Elevated Leverage And Debt LoadHigh debt relative to equity increases financial fragility, raises interest and covenant risk, and limits flexibility to absorb revenue volatility. With negative cash flows, elevated leverage materially increases refinancing and solvency risks, constraining strategic options and raising the cost of capital.
Holista Colltech Limited News
HCT FAQ
What was Holista Colltech Limited’s price range in the past 12 months?
Holista Colltech Limited lowest share price was AU$0.05 and its highest was AU$0.11 in the past 12 months.
What is Holista Colltech Limited’s market cap?
Holista Colltech Limited’s market cap is AU$29.43M.
When is Holista Colltech Limited’s upcoming earnings report date?
Holista Colltech Limited’s upcoming earnings report date is Aug 28, 2026 which is in 42 days.
How were Holista Colltech Limited’s earnings last quarter?
Holista Colltech Limited released its earnings results on Jan 29, 2026. The company reported -AU$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.002.
Is Holista Colltech Limited overvalued?
According to Wall Street analysts Holista Colltech Limited’s price is currently Overvalued.
Does Holista Colltech Limited pay dividends?
Holista Colltech Limited does not currently pay dividends.
What is Holista Colltech Limited’s EPS estimate?
Holista Colltech Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Holista Colltech Limited have?
Holista Colltech Limited has 367,834,350 shares outstanding.
What happened to Holista Colltech Limited’s price movement after its last earnings report?
Holista Colltech Limited reported an EPS of -AU$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Holista Colltech Limited?
Currently, no hedge funds are holding shares in AU:HCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Holista Colltech Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
212.00%
12-Months-Change
Fundamentals
Return on Equity
-321.20%
Trailing 12-Months
Asset Growth
72.50%
Trailing 12-Months
Company Description
Holista Colltech Limited
Holista CollTech Limited is a biotechnology firm with operations spanning Australia, Malaysia, and the United States. Its business activities are organized into four key divisions: Supplements, Ovine Collagen, Infection Control Solutions, and Food Ingredients. The company specializes in the production and distribution of dietary supplements, cosmetic-quality collagen, and a variety of health-conscious food ingredients. These innovative food products include low-glycemic index (GI) flour blends suitable for noodles, pasta, flatbreads, and other baked goods, along with low-sodium salt, reduced-fat fried options, and both less-calorie and low-GI sugar alternatives. Furthermore, Holista CollTech offers solutions for infection control. Its corporate headquarters are located in Subiaco, Australia.
Technical Analysis
Noumi Limited
―
Bioxyne Limited
―
Bubs Australia Ltd.
―
Nutritional Growth Solutions Ltd.
―
Clover Corporation Limited
―